Medtronic boost as CoreValve approval brought forward
This article was originally published in Clinica
Executive Summary
Medtronic’s CoreValve transcatheter aortic valve implantation (TAVI) system is now likely to get US FDA approval in April 2014, several months earlier than expected. The device will also not need to go through an FDA advisory panel, the company said, on the same day it presented positive data at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, currently being held in San Francisco, California.